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Table 1 Composition and characteristics of the as-synthesized GS NPs 
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Abstract. Novel hybrid biomaterial of gelatin-siloxane nanoparticles (GS NPs), with positive 
surface potential and lower cytotoxicity, was synthesized through a 2-step sol-gel process. The 
pDNA-GS NPs complex was formulated with high encapsulation efficiency, and exhibited and 
efficient transfection in vitro. We thus envision that the GS NPs material could serve as non-viral 
gene vectors for gene therapy. 
1. Introduction 
Gene therapy is considered to be a potential approach in the field of medicine, pharmaceutical 
sciences, and biotechnology as it eradicates disease at the level of genosome [1]. The major 
difficulty in gene therapy, however, is a need for safe and effective vector system that can deliver 
the gene to the target tissue and cells and allow for expression of the protein of interest over. 
Although vial vectors have efficient transfection, the potential oncogenicity, toxicity and 
immunogenicity of viral vectors persuade the development of non-viral vectors [2]. A number of 
non-viral gene delivery vectors, including lipid, synthetic cationic polymers, gelatin, chiotsan, and 
silica nanoparticles, have been explored [3]. However, the design of safe and efficient gene 
transfection vectors is still a challenge in gene therapy [4]. In our previous study, a new family of 
organic-inorganic hybrid with both of biodegradation and biocompatibility, could be easily 
developed by bridging of gelatin chains onto siloxane network through a sol-gel procedure [5]. In 
this study, we designed a novel kind of gelatin-siloxane hybrid nanoparticles (GS NPs), which 
could encapsulate plasmid DNA efficiently. Moreover, our in vitro experiments indicated that the 
fabricated GS NPs exhibited not only low cytotoxicity, but also high transfection for Hela cells in 
vitro.  
2. Materials and methods 
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Fig. 1 FTIR spectra of gelatin and GS NPs 
As shown in Table 1, appropriate amount of GPSM was added to 0.5% or 1% gelatin solution in 
HCl (pH 3.0) at 25 
o
C. After stirring for 30 min, ~ 40 µL of ammonia (25%) was subsequently added 
into the above mixtures till pH became 9.0. The mixtures were then continuous stirred for another 
24 h. Though the mixture was initially clear, continuous stirring gave a milky emulsion. The resulting 
GS NPs were purified by centrifugation (19,000 rpm, 30 
o
C, 15 min) for 3 times. GS NPs with 
diameter of ~ 200 nm were then mixed with DNA solution at predetermined weight ratios, 
following by 30 s vortex and 30 min incubation. NPs/pDNA complexes were also purified by 
centrifugation (19000 r.p.m., 30 
o
C, 15 min). In the following experiments, NPs/pDNA complex 
was finally suspended in deionized water, and the final concentration of pDNA was kept at 200 
µg/mL for each sample. 
Zeta potentials and size of nanoparticles were measured on a Nano-ZS zetasizer dynamic light 
scattering detector (Malvern Instruments). The FTIR transmission spectra were recorded by using a 
AVATAR360 FT-IR spectrometer (Nicolet) at a resolution of 4 cm
-1
, and 256 scans were taken in 
the range of 400 ~ 4000 cm
-1
. The amount of –NH2 on the surface of NPs were determined by using 
ninhydrin reaction, in which histidine was utilized as reference. To examine the binding of pDNA 
to GS NPs, gel electrophoresis assay was electrophoresed on 1 wt% agarose gel containing 1 µg/mL 
ethidium bromide in deionized water at 150 V for 45 min. 
For in vitro experiments, Hela cells were cultivated in DMEM (Dulbecco's Modified Eagle 
Media) supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/mL) and streptomycin 
(100 mg/mL) at 37 
o
C and 5% CO2. For MTT assay, 10
5
 cells were firstly seeded into 96-well plates 
and incubated for 24 h. The cell cultures were then exposed to 100 µL of serial test specimens, 
respectively. After 24 h co-incubation, medium was replaced with 20 µL MTT solution (5 mg/mL 
in PBS buffer) and further culture for 4 h. At the end of the assay, MTT solution was removed and 
100 µL DMSO was added to dissolve the blue formazan crystal by proliferating cells. The 
absorbance was measured at 570 nm using Bio-tek ELX800 microplate reader. The relative cell 
viability (%) was expressed as a percentage relative to the untreated control cells. 
For in vitro transfection experiments, Hela cells were firstly seeded into 6-well plates and 
incubated for 24 h. After removing the medium, 1 mL of serum-free DMEM containing serial test 
specimens was added into each well, and the concentration of DNA was set as for 1 µg/mL each 
well. The cell cultures were then co-incubated for 8 h. At the end, the medium was replaced with 
complete DMEM containing 10% FBS and the cells were allowed to grow for an additional 24 h. The 
β-galactosidase expression was measured in the cell lysate using a commercial kit, and the 
absorbance was determined at 415 nm on Bio-tek ELX800 microplate reader.  
3. Results and discussion 
At the initial acidic pH condition (within 30 
min), GPSM was subject to cleavage of the 
C-O bond in the epoxy group [6]. The 
protonated epoxy group is so activated to 
attack nucleophilic groups like NH2 on the side 
chain of gelatin so that GPSM molecules could 
be grafted to the gelatin chains. Simultaneously 
methoxy silane groups (Si-OCH3) of GPSM 
were hydrolyzed in acidic solution to give 
silanol groups (Si-OH). As adding ammonia to 
this precursor sol, the pH value of sol was 
changed into 9.0 immediately. The 
condensation reaction was thus quickly 
initiated at alkaline condition, resulting in a 
network of siloxane.  
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Fig. 4 Cytotoxicity of GS NPs by MTT assay.  
Fig. 3 Gel electrophoresis assay. ND: naked 
DNA; Lane 1–5: GS NPs/DNA complexes with 
the weight ratio (mg/mg) of 20, 50, 100, 200 
and 500, respectively. 
Table 1 showed the characteristics of GS 
NPs with different feed ratios. The size of 
NPs (from ~650 nm to ~150 nm) decreased 
with the concentrations of gelatin, whereas 
increased with GPMS. However, surface 
charges and amino groups of NPs were 
stable at the various concentrations of 
gelatin and GPSM. Fig. 1 compares FT-IR 
spectra of a typical GS NPs (G2) with 
gelatin. Both of gelatin and GS NPs had a 
peak of 1650 cm
-1
 corresponded to the C=O 
stretching. For GS NPs, the presence of new 
bands at 1030, 1140 and 458 cm
-1
, suggested 
that siloxane exists and can be respectively 
indexed to the asymmetric and symmetric 
stretching vibration of Si-O-Si as well as the 
bending of Si-O-Si.   
A critical requirement for effective gene 
delivery is their ability to condense 
string-like DNA molecules into compact 
nanosize particles suitable for cellular uptake 
[8]. The particle size and surface charge of a 
GS/DNA complex are important factors 
which may influence the access and passage 
of the complex into the cells. As shown in Fig. 
2, the sizes and the surface charges of the 
NPs/DNA complexes were dependent on the 
mass ratio of NPs/DNA. Namely, the size of 
complexes decreased with mass ratios, while 
the surface charge increased with mass 
ratios.  
The condensation capability of GS NPs 
with DNA was also evaluated by using 
agarose gel electrophoresis. It was observed 
in Fig. 3 that while free pDNA moved at its 
usual position, pDNA complexed with GS 
NPs with different mass ratios (20 to 500) 
exhibited partly immobilised within the wells 
in an electromobility shift assay (lane 1-5).  
Cytotoxicity is one of the vital issues for 
successful gene therapy. Some commercially 
available transfection agents such as PEI 
always result in high toxicity to cells [9]. As 
shown in Fig. 4, exposure to GS NPs, at the 
concentration < 200 mg/mL, led to the death 
of ~ 10% of cells. However, as the 
concentration of NPs increased to > 300 
mg/mL, cellular viability decreased to around 
60%. Our previous results indicated that the 
highest transfection efficiency exhibited at 1 
µg/mL of pDNA in complexes with vector. It 



















































Fig. 2 Size (columns) and zeta potential 
(diamonds) of GS NPs/DNA complexes. 
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Fig. 5 Transfection of Hela cells expressing 
β-gal using Lipofectamine
TM
 reagent (Lip) and 
GS NPs/DNA complexes. 
is thus suggested GS NPs might behave low 
cytotoxicity for in vitro transfection 
experiment in Hela cells as the weight ratio of 
GS : DNA < 200 : 1. 
The ability of GS NPs to deliver DNA into 
Hela cells was determined by performing 
a β-gal reporter gene transfection. The 
expressions of gene were taken at 
predetermined GS NPs/DNA mass ratios, as 
shown in Fig. 5. Highest transfection 




observed for cells pretreated with complexes 
formulated at mass ratio of 100 compared to 
weight ratios of 50 and 200. Considering that 
Lipofectamine
TM
 is highly competent vector 
used for in vitro DNA delivery, our results thus 




Novel organic-inorganic GS NPs were developed as potential gene vectors. The cationic GS NPs 
with size of ~ 200 nm showed low cytotoxicity and high encapsulated efficiency to pDNA. 
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